43 results about "Brain infarctions" patented technology

It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and / or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and / or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.

The present invention relates to a composition comprising a starch or total dietary fiber which improves the cell viability, specifically, the inventive starch and total dietary fiber isolated from the extract of Gramineae plant and the components therefrom improved the cell viability when the cells were incubated under hypoxic condition, or in the presence of beta-amyloid and 6-hydroxydopamine treatment, as well as prevented and treated myocardiac infarction, cerebral infarction and vascular dementia, or alleviated memory loss, all of which were proven using rats as the respective animal models. Therefore, they can be used as therapeutics or health care food for preventing and treating ischemic diseases or degenerative brain diseases.

The present invention discloses a thrombolysis oligopeptide-imidazolidine binary conjugate, a preparation method and uses thereof. According to the present invention, L-Lys is adopted as a linking arm to link 1,3-dioxy-2-[(4-oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline, ARPAK having a thrombolysis effect, GRPAK, RPAK or PAK to obtain the thrombolysis oligopeptide-imidazolidine binary conjugate represented by a formula I or II, wherein the thrombolysis oligopeptide-imidazolidine binary conjugate integrally has characteristics of nanometer structure, BBB crossing, thrombolysis and NO removing. The thrombolysis oligopeptide-imidazolidine binary conjugate has high NO free radical clearance activity, excellent thrombolysis activity and excellent antithrombosis activity. In vivo anti-stroke activity test results show that: with the thrombolysis oligopeptide-imidazolidine binary conjugate, nerve functions of stroke rats can be effectively protected, brain infarct volume of the stroke rats can be reduced, excellent anti-stroke activity is provided, and the thrombolysis oligopeptide-imidazolidine binary conjugate can be prepared into a clinical drug for brain infarction treatment.

The present invention discloses an RPAK / imidazolidine / RGD ternary conjugate, a preparation method and uses thereof. According to the present invention, L-Lys is adopted as a linking arm to link 1,3-dioxy-2-[(4-oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline, an RPAK tetrapeptide having a thrombolysis effect, and a RGD tetrapeptide having an anti-thrombosis effect to obtain the RPAK / imidazolidine / RGD ternary conjugate represented by a formula I, wherein the RPAK / imidazolidine / RGD ternary conjugate integrally has effects of BBB crossing, thrombolysis and NO removing. The RPAK / imidazolidine / RGD ternary conjugate has high NO free radical clearance activity, excellent thrombolysis activity and excellent anti-thrombosis activity. In vivo anti-stroke activity test results show that: with the RPAK / imidazolidine / RGD ternary conjugate, nerve functions of stroke rats can be effectively protected, brain infarct volume of the stroke rats can be reduced, anti-stroke activity is provided, and the RPAK / imidazolidine / RGD ternary conjugate can be adopted as a clinical drug for brain infarction treatment.

The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

The invention discloses a Chinese medicinal composition for treating brain infarction and its after-effects, which is prepared from the following Chinese medicinal herbs: gastrodia tuber 10g, hooked uncaria 10-30g, abalone shell 10-30g, white mustard seed 10-20g, fragrant solomonseal rhizome 10-30g, kudzuvine root 10-30g, Ligusticum wallichii 10-30g, spatholobus stem 10-30g, frankincense 5-15g, myrrh 5-15g, earthworm 5-10g, buthus martensi kirsch 6-10g, white-stiff silkworm 10-15g, giant typhonium tuber 5-10g, curcuma root 10-30g, Acorus calamus 5-10g, achyranthes and cyathula root 10-30g, licorice root 5-10g and leech 3-10g.

The invention which belongs to the technical field of medicines concretely relates to a Fasudil hydrochloride hydrate and a preparation method thereof. Fasudil hydrochloride prepared in the invention which has three and a half crystal waters has the advantages of high purity, good stability, unapparent weight gain of moisture absorption in a high humidity condition and good formability. The invention also relates to an application of the hydrate in preparing drugs for improving and preventing ischemic cerebrovascular diseases caused by a plurality of reasons, such as cerebral infarction, vertebrobasilar artery insufficiency, delayed cerebrovascular disease caused by subarachnoid hemorrhage, cerebral vasospasm caused by brain surgery and interventional therapies, and transient ischemic attack.

Pipecolic acid derivative-containing liposome preparations which are excellent in the immediate action and thus usable in an urgent situation such as brain infarction. These preparations are characterized by containing pipecolic acid derivatives or pharmaceutically acceptable salts thereof, which comprise the components as described in the description, as the active ingredient and lecithin as the major component of lipids forming liposomes, without resort to cholesterol as a stabilizer.

The invention relates to an alprostadil composite medicine comprising high-purity alprostadil and a mixture of aspirin-DL-lysine and sodium salicylate, wherein a weight ratio of aspirin-DL-lysine to sodium salicylate is 90-95:5-10. The invention also provides a weight ratio of the raw materials of the composite medicine. The invention also provides a preparation method of the alprostadil composite medicine, and a quality controlling method of the alprostadil composite medicine. With a pharmaceutically acceptable alprostadil composite medicine dosage, the medicine can be prepared into lyophilized injections, oral preparations, aerosols, suppositories, or enemas of the acceptable alprostadil composite medicine. The invention discloses chromatographic conditions for determining the contents of alprostadil, prostaglandin A1 and prostaglandin B1. Three peaks before an alprostadil peak are characteristic peaks of alprostadil composite medicine auxiliary materials. The alprostadil composite medicine is used for treating and preventing diseases such as coronary heart disease, myocardial infarction, brain infarction, hypertension, hyperlipemia, atherosclerosis, angiitis, tumour, hepatitis, diabetic angiopathies, kidney insufficiency, bronchial asthma, pancreatitis, gastric ulcer, and vertebrobasilar insufficiency.

The invention relates to the field of traditional Chinese medicines and particularly discloses a traditional Chinese medicine transdermal patch and a preparation method and application thereof. The effective components for preparing the traditional Chinese medicine transdermal patch comprise the following raw materials of, by weight, 2-4 parts of sanchi flower, 2-4 parts of saffron crocus, 2-4 parts of ligusticum wallichii, 1-3 parts of resina draconis, 2-4 parts of salviae miltiorrhizae, 2-4 parts of mountain pepper, 1-3 parts of levigating cinnabar, 1-3 parts of curcuma zedoary, 1-3 parts of scorpion, 1-3 parts of musk, 1-3 parts of hirudo, 1-3 parts of monkshood, 1-3 parts of astragalus, 1-3 parts of olibanum and 1-3 parts of curcuma aromatica. The raw materials are adjusted into an ointment through a ligusticum wallichii water decoction, and the traditional Chinese medicine transdermal patch has the characteristics of being convenient to use, safe in using, stable in component, obvious in effect, free of side effects and capable of treating mild brain infarction and mild coronary heart disease only through external application.

The invention discloses interferon regulatory factor 9 (IRF9) and application of an inhibitor thereof in cerebral apoplexy, belonging to the field of gene function and application. The invention uses IRF9 gene knock-out mice and brain-specific IRF9 transgenic mice as experimental subjects and adopts middle cerebral artery ischemia reperfusion model, results show that compared with mild type C57 mouse, the brain infarction volume of IRF9 gene knock-out mouse is apparently inhibited, and nerve function is improve remarkably, while the infarction volume of nerve-specific IRF9 transgenic mouse is apparently inhibited, and nerve function is deteriorated markedly. Therefore, IRF9 gene has nervous system function deterioration effect; especially, IRF9 gene can deteriorate cerebral apoplexy. As for the above function of IRF9, the invention provides application of IRF9 as drug target of cerebral apoplexy treatment in developing medicaments for treating cerebral apoplexy.

The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

The invention discloses a function and application of a Toll interacting protein (Toll-interacting protein, Tollip) gene in a stroke disease, and belongs to the fields of functions and application of genes. The Tollip gene knockout mice are taken as experiment objects, and the model is perfused by middle cerebral artery occlusion. The result shows that the brain infarction volume of the Tollip gene knockout mice is obviously reduced in comparison with that of wild-type control mice, the neurological function is obviously improved, and the cell quantity of brain death is also obviously reduced, so as to find that the Tollip gene can promote deterioration of the nervous system, and aggravate and promote occurrence and development of the stroke. The Tollip can be used as a drug target for screening a drug of treating the stroke, and a Tollip inhibitor can be applied to preparation of the drug for treating the stroke.

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic actionwherein each symbol is as defined in the specification.The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

The present invention provides a traditional Chinese medicine composition, which is prepared from salvia miltiorrhiza, cape jasmine, red peony root, tree peony root-bark and other bulk drugs. The traditional Chinese medicine composition is provided for treatments of obstruction of collaterals by blood stasis and kidney asthenia at a meridian collateral convalescent period of stroke, and syndromes of hemiparalysis, deviation of mouth and tongue, stiff tongue, hemianesthesia, dizziness, soreness and weakness of waist and knees, and the like at a convalescent period of brain infarction. In addition, the present invention further discloses a preparation method for the traditional Chinese medicine composition.

The invention discloses a traditional Chinese medicine composition for treating brain infarction. The composition is mainly prepared from, by weight, 140-150 parts of veronicastrum axillare, 5 parts of flos carthami, 6 parts of licorice roots, 10 parts of fructus viticis, 10 parts of rhizoma chuanxiong, 10 parts of radix scutellariae, 10 parts of radix angelicae, 10 parts of chrysanthemum flowers, 10 parts of mistletoe, 15 parts of uncaria, 15 parts of radix cyathulae, 15 parts of root poria, 15 parts of concha haliotidis, 15 parts of eucommia bark, 20 parts of Chinese wolfberry fruit, 20 parts of jujube peel, 20 parts of red-rooted salvia roots, 20 parts of gastrodia elata, 20 parts of tuber fleeceflower stems, 30 parts of radix astragali and 30 parts of red ganoderma lucidum. A preparation method includes the following steps that firstly, flos carthami, Chinese wolfberry fruit and jujube peel are directly dried and smashed; secondly, other medicines are cleaned and placed into a high-pressure pot to be steamed for 40 min and then taken out and dried till the water content is smaller than 7%, and the mixture is smashed; thirdly, the medicine powder is evenly mixed.

The invention discloses a semiconductor laser synthesizer therapeutic instrument. The semiconductor laser synthesizer therapeutic instrument comprises a semiconductor laser synthesizer and a control system. The semiconductor laser synthesizer comprises a laser dielectric crystal (4), a semiconductor laser unit (1), an optical coupling system (2), a reflector (3), an output mirror (5), a frequency-doubling crystal (6), a feedback mirror (7), a transmission optical fiber (9) and a focusing lens (8), wherein a laser resonant cavity is formed by the laser dielectric crystal (4), the reflector (3) and the output mirror (5), the frequency-doubling crystal (6) is placed between the output mirror (5) and the feedback mirror (7), and the focusing lens (8) is arranged behind the feedback mirror. The control system comprises a power module, a semiconductor laser synthesizer stable operation module and a system control module. According to the semiconductor laser synthesizer therapeutic instrument, the cavity-outside frequency doubling and fundamental wave feedback technology is adopted in cooperation with a circuit control system, so that the purpose of taking both efficiency and stability into consideration is well achieved; the semiconductor laser synthesizer therapeutic instrument can be effectively used for photodynamic therapy, and is used for carrying out laser irradiation on a nasal cavity or acupoints, and carrying out therapy on vascular headaches, brain infarction, post-traumatic brain syndromes and chronic cardiovascular and cerebrovascular diseases.

Intractable neuronal diseases are treated by inducing differentiation of neural stem cells into neurons without accompanying a risk such as cytotoxicity and infection. Intractable neuronal diseases, such as Parkinson's disease, cerebral infarction, Alzheimer's disease, spinal cord injury, brain contusion, amyotropic lateral sclerosis, Huntington's disease, malignant tumor, and the like, are treated by regeneration therapy by transferring VHL peptides which can induce differentiation of neural stem cell into neurons into neural stem cells to induce differentiation of neural stem cells into neurons or by administering VHL peptides directly into a human body to induce differentiation of endogeneous stem cells into neurons.

Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof.More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

The invention discloses application of a primordial energy strengthening and brain infarction treating medicinal composition to the preparation of medicaments for treating senile vascular dementia. Compared with a control group, namely oral aniracetam, oral primordial energy strengthening and brain infarction treating capsules can effectively improve the living ability of a patient and have obvious advantages in the aspects of mini-mental state examination scale and symptom integral evaluation of traditional Chinese medical science.

The invention relates to foods, in particular to a health food of bacillus natto fermented fluid milk and a production method thereof. The health food is a natto kinase dairy product obtained from bacillus natto fermentation fluid milk, for every 100 weight parts of fluid milk, 10 or less than 10 weight parts of edible grade glycerin and 10 or less than 10 weight parts of a sweetening agent are added, and the natto kinase activity of 100ml end product is higher than 3000 IU. The health food which is cheap and at the same time very good is provided for patients with coronary heart disease, brain infarction, arteriosclerosis, hypertension, hyperlipidemia, hyperglycemia, high blood viscosity, hyperuricemia and gout, as well as general population. The health food has the advantages that raw materials are easy to access, the formulation is simple, the fermentation time is short, the taste is sweet, cane sugar is not contained, the content of purine is low, and edible safety and convenience are achieved. A user not only can absorb nutrient content in milk or goat milk, but also can absorb nattokinase having multiple health-caring functions, and the health food has a popularization and promotion value. According to the invention, a novel fermented milk field and consumer groups thereof are widened for dairy industry.

The invention belongs to the biomedical field, and mainly relates to application of growth hormone releasing hormone receptor agonist MR-409 in preparation of drugs for preventing and treating ischemic brain infarction. The MR-409 is a novel GHRH receptor agonist, and preliminary researches prove that the MR-409 is capable of reducing pathological injury of refractory diseases such as diabetes mellitus and myocardial ischemia by increasing survival of multiple bone marrow stem cells in an ischemic focus. Researches in the invention prove that the MR-409 is capable of remarkably improving ischemic brain injury, survival rate and neurobehavioral manifestations of model mice with cerebral ischemia possibly through a mechanism of increasing proliferation, migration and survival of endogenous neural stem cells. The researches provide new strategies for treatment of the cerebral ischemia, have important clinic treatment significances and provide scientific and theoretical foundations for research and development of drugs utilizing regeneration of nerve cells as cerebral ischemia treating targets in future.

The invention is directed to a compound of the formula I wherein the variables are as defined herein, or a stereoisomeric form thereof, mixture of stereoisomeric forms, in any ratio, or a salt thereof. Another aspect of the present invention is directed to a pharmaceutical composition comprising, a pharmaceutically effective amount of one or more compounds of formula I according to claim 1 in admixture with a pharmaceutically acceptable carrier. The invention is also directed to a method for effecting the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunological or metabolism-associated acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism, for the treatment of ulceration, atheroscleroses and stenoses, and for the treatment of inflammations, cancer diseases, tumor metastasis formation, cachexia, anorexia, cardiac insufficiency and septic shock or for the prophylaxis of myocardial and cerebral infarctions, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound of formula I according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof. Furthermore the invention is directed to a method for preparing a compound of formula I.

The present disclosure provides an operating method of an automatic brain infarction detection system on magnetic resonance imaging (MRI), which includes steps as follows. Images corresponding to different slices of a brain of a subject are received from the MRI machine. The image mask process is performed on first and second images of the images. It is determined whether the cerebellum image intensity and the brain image intensity in the first image are matched. When the cerebellum image intensity and the brain image intensity are not matched, the cerebellar image intensity in the first image is adjusted. The first image is processed through a nonlinear regression to obtain a third image. A neural network identify an infarct region by using the first, second and third images that are cut.

The invention discloses a traditional Chinese medicine capsule for treating massive brain infarction. The traditional Chinese medicine capsule is prepared from the following traditional Chinese medicinal materials in weight proportion: 20 parts of ligusticum wallichii, 20 parts of evening primrose oil, 15 parts of fructus aristolochiae with round roots, 15 parts of manis pentadactyla, 10 parts of leeches, 12 parts of bombyx batryticatus, 10 parts of herba erigerontis, 8 parts of teucrium viscidum, 12 parts of syringa pinnatifolia, 6 parts of lobelia pleotricha, 8 parts of mature coconut fruit, 4 parts of hydrangeaceae pileostegia viburnoides, 12 parts of keruing, 4 parts of copperleaf herb, 6 parts of triglochin maritimum, 5 parts of citrullus colocynthis, 5 parts of sapium baccatum, 6 parts of wild semen canavaliae, 6 parts of aizoon stonecrop herb and 6 parts of pine pollen disruption powder. Clinical experiment results prove that through selecting the proper traditional Chinese medicinal materials according to the ratio, the capsule achieves the remarkable efficacy for treating massive cerebral infarction, and is safe and free of toxic and side effect.

The invention relates to a Chinese medicinal freeze dried powder for treating acute brain infarction and process for preparation, wherein the medicament is prepared from musk, curcuma aromatica, cape jasmine and borneol through dressing the raw material herbs, making medicinal preparation and carrying out detection, and controlling the content of active constituents in the freeze-dried powder injection. The medicament of the invention has the effects of heat-clearing, purging the pathogenic fire, removing heat from blood and detoxification.